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Abstract
Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers; however, familial
forms are believed to account for up to 30% of some cancers. In Hispanics, the most commonly diagnosed
hereditary cancers include colorectal cancer syndromes such as, Lynch Syndrome, Familial Adenomatous Polyposis,
and hereditary breast and ovarian cancer syndromes. Although the incidence of hereditary cancers is low, patients
diagnosed with hereditary cancer syndromes are at high-risk for developing secondary cancers. Furthermore, the
productivity loss that occurs after cancer diagnosis in these high-risk patients has a negative socio-economic
impact. This review summarizes the genetic basis, phenotype characteristics, and the National Comprehensive
Cancer Network’s screening, testing, and surveillance guidelines for the leading hereditary cancer syndromes. The
aim of this review is to promote a better understanding of cancer genetics and genetic testing in Hispanic patients.
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Background
Hereditary cancer overview
According to the 2010 census, Hispanics comprise
16.3% of the population in the United States (US) [1]. By
2050, the Hispanic population is estimated to become
25% of the US population. Hispanics are a mixed group
of individuals from across Latin America and the Carib-
bean and are defined as individuals that share a culture
and language that is linked to the historic migrations
that started from Spain that led to the discovery of the
Americas. In the year 1492, Christopher Columbus
crossed the Atlantic Ocean and reached the Americas.
The arrival of Columbus to the Americas led to the start
of the “Colonization of Americas”, where language, cul-
ture and religion was instituted by the Spaniards, but
also other European countries such as Portugal.
Spaniards introduced new diseases to the Americas
leading to the death of most of the Indigenous population
of the Americas. Due to the high mortality of Indigenous
population, Africans (mostly from West Africa) were intro-
duced in the Americas. Through these historic migrations,
the Hispanic population was created. These populations
had great levels of genetic and cultural admixture from the
three major racial ancestral populations: Europeans,
Africans, and Indigenous. However, the variability ob-
served in Hispanic admixture, is concordant with the
local history of the country of origin [2]. For instance,
Hispanics from the Caribbean (including Puerto Ricans)
have a higher proportions of West African compared to
Hispanics from South America, which have higher
European and Amerindian ancestry [2].
Cancer is a major public health problem and the lead-
ing cause of death among Hispanics worldwide [3]. Ma-
lignancies, such as breast and colorectal cancers, when
diagnosed in individuals younger than 50 years, are likely
caused by inherited mutations and often are aggressive
leading to a worse prognosis [4]. With the availability of
efficient screening methods for both breast and
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colorectal cancer, these cancers may be prevented or di-
agnosed at early, more treatable stages in Hispanics,
minimizing the burden of these diseases in this popula-
tion [5]. By identifying individuals at high-risk and estab-
lishing tailored early detection and preventive strategies,
the economic productivity loss, morbidity, and mortality
may be significantly reduced.
In this article, we provide a summary of the genetic
basis for three of the leading cancers in Hispanics
(breast, ovarian, and colorectal cancer), which have
known hereditary contributions. We will discuss the
clinical presentation of these cancers in Hispanics and
how it differs from other populations. Furthermore, we
will discuss the role of multigene testing in advancing
genetic testing services in Latino populations.
Hereditary breast cancer and ovarian cancer (HBOC)
Breast cancer (BC) represents approximately 29% of all
cancer cases in US Hispanic women [3]. Ovarian cancer
(OC) is the 8th cancer with the highest incidence and
the 5th leading cause of cancer death among US
Hispanic women [3]. Approximately, 5–10% of all BC
are caused by mutations in highly penetrant susceptibil-
ity genes [6]. Mutations in the BRCA1 and BRCA2 genes
account for approximately 25% of hereditary BC and
15% of all OC [7]. Women with mutations in these
genes have up to an 87% lifetime risk of developing BC
by age 70 and up to a 44% risk of OC [4, 8].
Mutation spectrum
In Hispanics, deleterious BRCA mutations have been
found in approximately 25% of women with BC [9]. The
majority of the studies reporting the prevalence of BRCA
mutations in Hispanics have been performed on hetero-
geneous groups of Hispanic women from different coun-
tries, including: Mexico [9–11], Brazil [12–14], Costa
Rica [15], Chile [16, 17], Argentina [18], Peru [19],
Colombia [20, 21], Venezuela [22], Bahamas [23], Cuba
[24], and Puerto Rico [25] (Table 1). Recently, BRCA
mutations in Latin American countries was published,
which detailed the mutations found and how the preva-
lence changed from country to country [26]. All of these
studies have shown that the BRCA mutation spectrum
varies according to the country of origin. For example,
women from Argentina, Mexico, and Brazil have a
higher prevalence of BRCA1 mutations [13, 18, 27],
whereas in women from the Caribbean (Cuba and
Puerto Rico), BRCA2 is more frequently mutated [24,
25]. Studies of women with BC from Spain showed a lar-
ger number of rearrangements in both BRCA genes
when compared to Hispanic women [28–30]. Addition-
ally, several mutations for both BRCA genes were found
in Hispanic subpopulations, especially in Argentina
where there is a higher proportion European admixture.
Furthermore, a mutation (BRCA2 c.156_157insAlu) from
Portugal was identified in the Northern/Central region
and accounted for one-fourth of the BRCA1/2 mutations
[31]. This same mutation was identified in several fam-
ilies of Brazil [31, 32].
Several populations have shown the presence of
founder mutations, which include some Ashkenazi Jew
mutations (BRCA1 185delGA; BRCA1 5382insC) ob-
served in Mexico [33], Peru [19], and Brazil [13]. These
founder mutations have also been reported in Spain
[28–30]. Therefore, these Ashkenazi Jew mutations are
thought to come from areas of Spain where Jews com-
munities settled during the early Common Era. The
BRCA1 ex9-12 deletion found in Mexican women is also
a founder mutation. This mutation has not observed in
Spain or South American populations, and was found to
pre-date Spanish colonization since it is estimated to
have arisen approximately 1,480 years ago [10, 34, 35]
(Table 1). Furthermore, two additional founder muta-
tions of Galician and Spanish origin were found in Spain
[28]. Of these, the BRCA1 c.211A > G Galician founder
mutation was found in the groups of a US Hispanic and
the Argentinian cohort [11, 18]. Three additional founder
mutations: 2 in BRCA1 (BRCA1 c.3331_3334delCAAG
and BRCA1 c.5123C > A) and 1 in BRCA2 (BRCA2
c.2806_2809delACAA) where described in Hispanics from
Colombia [21]. These Colombian founder mutations were
found in individuals that share the same haplotype, and
therefore share a common ancestor [21]. The BRCA2
c.3922G > T mutation has only been identified in the
Puerto Rican cohort, and in US Hispanic studies that in-
clude Puerto Ricans and not in other Latin American
countries [26]. In Portugal, the BRCA2 c.156_157insAlu
mutation seen in families of Portuguese descent was
also identified as a founder mutation that occurred
around 558 years ago [31, 32, 36]. Moreover, the
BRCA1 c.5266dup mutation was identified as a founder
Brazilian mutation of Eastern European origin [37].
The presence of these founder mutations in Latin
America is tightly linked to migration patterns that
shaped the genetic background of each Hispanic sub-
population up to present-day.
Several studies suggest that the prevalence of BRCA
mutations in Hispanic women is higher than the preva-
lence of BRCA mutations among Ashkenazi Jews and
non-Hispanic Whites [9, 11]. However, these observa-
tions are based on the predictability of BRCA genetic
risk models that use non-Hispanic White women as ref-
erence to determine risk, thus the prevalence of BRCA
mutations might differ from what has been reported [9].
Differences observed in the BRCA mutation spectrum of
Hispanic populations could be due to variations in the
contribution of each ancestral population to the genetic
background of the Hispanic subgroups. In addition,
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there is very limited information on the mutation
spectrum in some countries, such as Costa Rica,
Bahama, and Cuba, among others. Therefore, the muta-
tion spectrum of BRCA among Hispanic women is still
understudied, which may our knowledge on the true
percentage of BC in Hispanic populations that may be
attributable to hereditary changes.
Clinical phenotype
The clinical presentation of HBOC among Hispanic sub-
populations is very similar to non-Hispanic cohorts [12,
17, 19, 21, 25, 36–40]. Most studies reported that the ma-
jority of women that met inclusion criteria had BC diag-
nosed before age 50 (67.5%; range: 50.4–81.4%).
Additionally, family history of BC was found on an aver-
age of 16.1% (range: 5.2–27%) of Hispanic women
recruited in the studies described in this review. Compari-
sons of the age at BC diagnosis among the Hispanic sub-
populations described above showed that Caribbean
Hispanics (Bahamas, Puerto Rico and Cuba) were diag-
nosed at later ages (mean: 45.9 years; range: 40–51.8 years)
than their South American (mean: 44 years), Central
American (mean: 41.6 years) and US Hispanic (mean:
38.5 years) counterparts [17, 19, 21, 25, 28–30, 32, 36–41].
Clinical guidelines
The National Comprehensive Cancer Network (NCCN)
established guidelines for physicians to evaluate potential
candidates for genetic counseling and testing [42]. The
evaluation criteria for HBOC genetic testing include: per-
sonal history of BC before 50 years of age, one or more 1st
degree relatives with BC, family history of a BRCA1/2
mutation, and personal history of OC, among others. The
information obtained from the genetic tests is used by
physicians to guide the patient’s medical/surgical manage-
ment. This management may include chemoprevention
therapy, prophylactic surgery (double mastectomy, oo-
phorectomy, and/or hysterectomy), and increased surveil-
lance by mammography and breast MRI. Even though
these guidelines have been established, underutilization of
these guidelines for Hispanic patients that meet the cri-
teria has been reported [43]. The reason for the low ad-
herence to these guidelines is yet to be addressed, but it is
believed that a combination of factors such as, socioeco-
nomic, belief systems, and access to care contribute to this
health disparity. Furthermore, the benefits of utilizing
these guidelines in other countries, where prevalence of
BRCA mutations is high, is still to be determined. For ex-
ample, the high prevalence of BRCA mutations in the
Bahamas supports the implementation of universal test-
ing. However, countries such as Puerto Rico, that have a
small number of mutations, could benefit even more from
implementing these guidelines. Additionally, it is import-
ant to note that these guidelines where developed using
studies mainly performed in non-Hispanic White women.
Further studies are needed to elucidate whether NCCN
guidelines are useful in Hispanic women or if the differ-
ences observed in the prevalence of BRCA mutations and
clinical presentation, warrants changes to accommodate
these differences.
Colorectal cancer syndromes
Colorectal cancer (CRC) accounts for 11 and 8% of can-
cers in US Hispanic males and females, respectively [3].
Hereditary CRC accounts for approximately 5–10% of all
CRC cases. There are two major types of inherited CRC
syndromes: 1) Familial Adenomatous Polyposis (FAP) and
2) Lynch Syndrome (LS). In this section, we will discuss
the clinical presentation, genetic basis, and guidelines for
testing for these two forms of inherited CRC syndromes.
Familial adenomatous polyposis
FAP is characterized by the presence of hundreds to
thousands of adenomatous polyps in the colon and rec-
tum. These polyps appear during adolescence and, if left
untreated, can develop into CRC by age 40. Affected in-
dividuals without a colectomy have close to 100% life-
time risk of developing CRC [44]. By age 20, most
patients have at least 1 adenomatous polyp; by age 50,
most have developed adenocarcinoma [44]. Thus, the
recommended treatment for FAP is prophylactic colec-
tomy in young adulthood [45].
Classic FAP has an incidence ranging from 1 in 8300
people to 1 in 22,000 people, depending on the country
of origin [46]. FAP is caused by mutations in the APC
gene [47]. Most cases have a family history of FAP, but
close to 25% of cases are diagnosed as de novo mutations
[48]. Identifying the specific APC mutation in a family
can be used for targeted sequencing testing for pre-
symptomatic, at-risk family members.
Mutation spectrum The FAP mutation spectrum has
been studied in a limited number of Hispanic countries,
including Brazil [49], Argentina [50], Peru [51], Mexico
[44], Puerto Rico [52], Portugal, and Spain [53] (Table 2).
Most mutations identified in Hispanic patients from
both Latin America, Portugal, and Spain have been in
exon 15 of the APC gene (Table 2). This exon comprises
more than 75% of the coding sequence and is the most
commonly mutated region of the APC gene [54].
Clinical phenotype The data available on the clinical
manifestation of FAP in Hispanic is limited. Of the stud-
ies discussed, only studies from Puerto Rico [52], US
Hispanics (from Mexico, Guatemala and Honduras) [51]
and Brazil [49] had phenotype information for Hispanic
FAP patients. Puerto Rican individuals with FAP had a
mean age of diagnosis of 27.6 years (range: 9–71 years),
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Table 2 APC mutation spectrum in Hispanic patients
APCa
Study Population n Exons Mutation Protein Change




14 c.1873C > T p.Gln625*
15 c.4012C > T p.Gln1338*




8 c.904C > T p.Arg302*
15 c.4348C > T p.Arg1450*
15 c.3880-3881delCA p.Gln1294Glyfs*6
8 c.847C > T p.Arg283*




Zeichner S et al. 2012 [41] Hispanic 1 15 c.3927_3931delAAAGA p.Glu1309Aspfs*4
Ricker C et al. 2010 [42] Mexico, Guatemala, Honduras 9 15 c.3184C > T p.Gln1062*
15 c.3709delCA (MX) p.Gln1237Glufs*2
g.89926-?_141606 + ?del (GU)
15 c.3927_3931delAAAGA (MX) p.Glu1309Aspfs*4
15 c.3803_3815del1 (HO) p.Pro1268Glufs*16
15 c.3183_3187delACAAA (MX) p.Gln1062*
InSIGHT [53] Argentina 15 c.3920 T > A (missense) p.Ile1307Lys
Portugal 15 c.4687dup p.Leu1563Profs*4
15 c.5826_5829delCAGA p.Asp1942Glufs*27
Spain 5 c.637C > T p.Arg213*
6 c.707delA p.Gln236Argfs*57
7 c.730_731delAG p.Arg244Valfs*7
7 c.802G > T p.Glu268*
8 c.858delT p.His286Glnfs*7
8 c.904C > T p.Arg302*
11 c.1412delG p.Gly471Aspfs*27
13 c.1682dupA p.Thr562Aspfs*19
13 c.1690C > T p.Arg564*




15B c.2413C > T p.Arg805*
15C c.2496delC p.Ser833Alafs*9
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the majority were male (51.6%), and had ≥ 100 polyps in
their colon (67.7%) [52]. In addition, upper gastrointes-
tinal polyps and desmoid tumors were observed in 41.9
and 9.7% of the study subjects, respectively. Ricker et al.
described 9 Hispanic women from different regions with
FAP with a mean age of diagnosis of 37.2 years. Among
these women the most common extracolonic manifest-
ation as upper gastric polyps [51]. The study describing
Brazilian FAP patients reported that subjects had a mean
age of 32.6 years (7–67 years), 79% had upper gastro-
intestinal polyps, and 54% had desmoid tumors [49].
The prevalence of extracolonic manifestations in the
FAP patients of the Brazilian cohort was higher than in
other Hispanic subpopulations. In summary, the clinical
manifestations of FAP in Hispanics are similar to the
one presented by non-Hispanic US Whites.
Clinical guidelines To guide genetic testing for FAP in
individuals at high-risk, both the NCCN and the Ameri-
can Gastroenterology Association (AGA) have developed
guidelines for physicians. The NCCN guidelines recom-
mend genetic counseling for individuals with a personal
history of ≥20 colorectal adenomas, known APC dele-
terious mutation in the family, and personal manifest-
ation of a desmoid tumor, cribriformular variant of
papillary thyroid cancer, or hepatoblastoma [55]. Guide-
lines from the AGA for genetic counseling and testing
include, personal history of >10 cumulative colorectal
adenomas, family history of FAP, and family history of
FAP-type extracolonic manifestations [56].
Lynch Syndrome (LS)
LS accounts for 2–4% of all CRC cases [44]. This syn-
drome is characterized by CRC at an early age and a
high risk for a number of additional primary cancers,
including endometrial and gastric cancer [57]. Ap-
proximately 1 in 35 individuals diagnosed with CRC
has LS [58]. During their lifetime, individuals with LS
will have up to a 70% risk of developing CRC [58];
women will have up to a 45% risk of developing endo-
metrial cancer [59].
Mutation spectrum Germline mutations in the DNA
mismatch repair (MMR) genes, MLH1, MSH2, MSH6,
PMS2 and EPCAM, causing the absence of MMR pro-
tein expression result in LS [60]. The most common
genes mutated in LS are MLH1 and MSH2; close to 50%
of LS individuals have a mutation in MLH1 [61]. In a re-
view published by Dominguez-Valentín et al., the LS
mutation spectrum in South American countries was de-
scribed [62]. Pathogenic mutations in the MMR genes
were identified in patients from Brazil [53], Argentina
[63], Uruguay [64], and Colombia [65] (Table 3). Fur-
thermore, the InSIGHT database contains additional in-
formation on MMR mutations in additional Hispanic
subpopulations, Portugal, and Spain [53]. As seen in non
Hispanic Whites, mutations in the MLH1 gene are more
common in Hispanic, Portuguese and Spanish popula-
tions, with the exception of Uruguay [64] and Caribbean
Hispanics (Puerto Rico) [66] (Table 3). Data from Carib-
bean Hispanic patients showed that the mutation
spectrum consisted mostly of MSH2 mutations (66.7%),
followed by MLH1 mutations (25.0%) [66]. Mutations in
the MSH6 gene have only been identified in the Carib-
bean Hispanics [66], Brazilians [53], Chileans [67], and
Cubans [53]. There are no published mutations in the
EPCAM gene among Hispanics cohorts. The mutation
spectrum of MMR genes in Hispanic subgroups could
be more varied, thus, additional studies in Hispanic sub-
populations are needed.
Clinical presentation For MLH1 mutation carriers,
the CRC lifetime risk has been shown to be as high
as 68% [68]. The prevalence of MSH2 mutations in
families with LS has been reported to range from 38
to 54%, with a CRC lifetime risk of up to 68% [69].
The clinical presentation of LS in the Hispanic sub-
groups, is similar to what has been observed in NHW
with a mean age of diagnosis of 30–44 years of age,
endometrial cancer being the 2nd most common LS-
associated cancer, and colorectal tumor predominantly
in the right colon [62].
Table 2 APC mutation spectrum in Hispanic patients (Continued)
15D c.2838_2839delAT p.Cys947Phefs*15







aMissense mutations pathogenicity status was verified as pathogenic or likely pathogenic by the following databases: ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/) and Invitae (http://clinvitae.invitae.com/)

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cruz-Correa et al. Hereditary Cancer in Clinical Practice  (2017) 15:3 Page 12 of 15
Clinical guidelines The identification of at-risk individ-
uals for LS includes the clinical profile of the patient and
molecular testing. The NCCN has published clinical
guidelines to determine a patient’s risk of having LS [55].
The Amsterdam and Bethesda criteria were established
to help identify individuals that may harbor germline
mutations in the MMR genes based on personal and
family history of CRC [70]. The American Gastroenter-
ology Association (AGA) also provides guidelines for the
identifying at risk individuals and additionally guidelines
for the screening of CRC among these LS individuals
[71]. The AGA guidelines for LS testing are: to test
MMR deficiency in newly diagnosed CRC cases, and to
test individuals with CRC diagnosed at age ≤70 or individ-
uals older than 70 years of age who have a family history
of LS [71]. Moreover, the AGA guidelines for screening
for LS in these high-risk individuals or those affected by
LS suggest colonoscopies every 1 to 2 years starting at age
20–25 or starting 2 years younger than the youngest age
at CRC diagnosis in the family [71]. Additional studies are
needed to determine the utilization of established guide-
lines for Lynch Syndrome in Hispanics.
In addition, assessment of molecular markers in tu-
mors, such as microsatellite instability (MSI) or loss of
MMR protein expression, are used as molecular screen-
ing tools for identifying LS patients. Loss of MMR pro-
tein expression correlates with the presence of MSI and
is indicative of a possible germline MMR gene mutation
[72]. Genetic testing for LS is considered the “gold
standard” for diagnosis. However, lack of detection of
MMR protein expression by immunohistochemistry
(IHC) can be a surrogate marker to diagnose LS when
genetic testing is not available, due to limited accessibil-
ity to this type of test (lack of insurance coverage, eco-
nomic hardships, limited infrastructure). Current NCCN
and AGA guidelines recommend that genetic testing be
offered to at-risk patients if the test influences the med-
ical management of their condition or that of their at-
risk relatives. However, an important concern is that
these criteria may miss LS patients who do not meet cri-
teria. LS screening of all CRC tumors has been shown to
be cost-effective and is currently recommended by mul-
tiple professional societies [55, 71]. As many as 1/3 of
women with LS may initially present with endometrial
cancer without a history of CRC, thus universal screening
for LS in endometrial cancer has also been proposed [73].
Currently, there are no reports in the literature on univer-
sal testing of Lynch Syndrome in Hispanic subgroups
using IHC detection of MMR proteins, in contrast with
non-Hispanic whites for which data is abundant.
Multi-gene panel testing
The Supreme Court of the US invalidated the patents
made by Myriad Genetics© that gave them the right to
exclusively offer BRCA genetic testing. This ruling per-
mitted additional methods to sequence the BRCA gene,
as well as other genes, thus significantly reducing costs
for genetic testing. Furthermore, major breakthroughs in
next-generation sequencing (NGS) and a more compre-
hensive understanding of the genetic basis underlying
hereditary cancers are shifting genetic testing for heredi-
tary cancer from single gene testing to multiple gene
panels. Several of the commercial companies offering
cancer genetic screening are offering panels comprised
of dozens of genes, including BRCA1/2 and the MMR
genes, among others. Multi-gene testing would be espe-
cially beneficial to families who present a spectrum of
different cancer types. Furthermore, the current reduced
cost of NGS technology will allow laboratories across
Latin America to perform studies on patients with the
cancer syndromes discussed above to continue under-
standing the mutation spectrum and prevalence of mu-
tations of Hispanic populations.
Although the future of hereditary cancer testing will
undoubtedly reside in multi-gene panel testing, it pre-
sents some important challenges. Multi-gene panels in-
clude moderate penetrance genes with limited clinical
utility. Furthermore, for many of the known hereditary
cancer genes, is not clear whether the identification of a
deleterious mutation warrants clinical measures beyond
increased surveillance, particularly among understudied
ethnic groups such as Hispanics [74]. In addition, multi-
gene panel testing is likely to result in the identification
of a higher number of variants of uncertain significance
(VUS) and mutations with an undetermined clinical
value. Currently, a lack of standardization across genetic
laboratories regarding the analysis of the data as well as
the clinical interpretation of results may lead to errone-
ous medical advice [75]. As research, education, and
health policy development advances, these issues are
likely to be resolved.
Conclusion
Over the last 10 years, the scientific community has con-
ducted research to determine the prevalence and muta-
tion spectrum of the genes associated with hereditary
cancer syndromes in Hispanic populations. Genetic test-
ing is an integral part of the treatment for cancer pa-
tients. As the standard of care in hereditary cancer
testing shifts from single gene testing to multi-gene
panel testing, it will be essential that ongoing research
efforts focus on determining mutation penetrance and
associated genetic risks. This information will ensure
that the standard-of-care genetic testing is provided to
all patients in need and that patients will have access to
the latest advances in prevention and treatment of her-
editary cancers. Examination of barriers to genetic
testing and implementation of culturally sensitive
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educational programs will be essential to increase adher-
ence. Moreover, integration of clinical genetic guidelines
to health policy will enable implementation and sustain-
ability of genetic medicine across Hispanic populations.
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